Business ❯ Healthcare ❯ Pharmaceuticals

Weight Loss

Eli Lilly Novo Nordisk Wegovy GLP-1 Drugs GLP-1 Medications Partnerships GLP-1 Treatments Tirzepatide Anti-Obesity Therapies Market Trends Mounjaro Cash-Pay Market Compounded Medications GLP-1 Therapy Drug Approval GLP-1 Therapies Obesity Treatments

Lilly Still Dominates GLP‑1 Market as New Rivals Gain Traction

Rising trial wins for small firms plus new oral pills are testing Lilly's revenue‑heavy lead.

Retailers Move to Fill $50 Medicare GLP‑1 Prescriptions

Lilly Expands Neuroscience Pipeline With $2.8 Billion Purchase of AtaiBeckley

Novo Nordisk Narrows Gap With Lilly as Wegovy Pill Leads Early Oral Sales

Novo Nordisk Lifts 2026 Outlook as Wegovy Pill Powers Big Q1 Beat

Lilly’s Foundayo Start Trails Wegovy as Street Stays Positive

Lilly Shares Slip as Foundayo’s Second-Week Prescriptions Trail Wegovy

Novo Nordisk Extends Weight‑Loss Lead as Amgen’s Once‑Monthly MariTide Reaches Phase 3

Novo Nordisk’s Oral Wegovy Debuts With Strong Prescriptions as BMO Stays Cautious

States Curb Medicaid Coverage as First GLP‑1 Weight‑Loss Pill Debuts and Cash Prices Fall

Novo Nordisk Files for 7.2 mg Wegovy Dose After Stronger Weight-Loss Results